STAT News, March 27, 2025: We explain why RFK Jr’s plan to cut 3,500 FDA staff will be “extremely disruptive and not productive” for at least a few years. Reviewers and inspectors’ productivity will be hurt even if they are not cut and as a result patients and industry will be harmed because new drugs and devices will not be reviewed as quickly or as carefully. RFK’s plans to improve infant formula and food safety more generally will require more staff, not fewer. Why were these cuts decided before the new FDA Commissioner was in place at the FDA and had the opportunity to decide what would be best for the agency and the public?
Read More »News That Quotes Us & Our Work
We are often quoted in major newspapers and magazines, and on well-respected TV shows, radio programs, and websites where we share our opinion on issues that matter to you and your health. Stay up to date on health news and our take on it by reading the articles in this section.
‘Operation Stork Speed’: HHS, FDA Launch Plan for More Testing, Scrutiny of Infant Formula Ingredients
The Defender, March 19, 2025: Operation Stork Speed will require increased testing for heavy metals and other contaminants in infant formula and will review nutrients. NCHR points out that a new Consumer Reports investigation found arsenic, lead, and PFAS in several types of infant formula, which confirms that this effort is long overdue.
Read More »ADHD Drugs Under Scrutiny by RFK Jr.’s Make America Healthy Again (MAHA) Commission
Everydayhealth.com, March 17, 2025: President Trump’s executive order will create a MAHA Commission to examine the use of ADHD and psychiatric drugs for children. This news article focuses on whether access to ADHD drugs will harm children. NCHR reassures parents that access is unlikely to be harmed. We view the Commission as a good idea, but those views were not included in the article.
Read More »As Trump Administration Probes Long-Approved Medications, Could FDA Revoke Approvals?
Medscape March 6, 2025: MAHA Commission will study psychiatric, ADHD, and weight loss drugs’ impact on children. NCHR’s Diana Zuckerman agrees we need better evidence that the benefits of these drugs outweigh the risks.
Read More »Pfizer hires FDA drug regulator Cavazzoni, sparking revolving door debate
Politico, February 24, 2025: FDA Director of Drug Center (CDER), Cavazzoni, returns to Pfizer, where she worked before going to the FDA. NCHR and other experts say this revolving door undermines trust in the FDA and highlights concerns about the cozy relationship between the FDA and industry that can weaken standards of safety and effectiveness.
Read More »